1.
Evid. actual. práct. ambul
;
20(2): 41-41, 2017. tab
Article
Dans Espagnol
| LILACS
| ID: biblio-1128707
Sujets)
Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Quinolinone/usage thérapeutique , Broncho-pneumopathie chronique obstructive/traitement médicamenteux , Agonistes des récepteurs béta-2 adrénergiques/usage thérapeutique , Association de fluticasone et de salmétérol/usage thérapeutique , Glucocorticoïdes/usage thérapeutique , Glycopyrronium/usage thérapeutique , Indanes/usage thérapeutique , Administration par inhalation , Essais contrôlés randomisés comme sujet , Quinolinone/effets indésirables , Antagonistes muscariniques/usage thérapeutique , Broncho-pneumopathie chronique obstructive/mortalité , Association médicamenteuse , Association de fluticasone et de salmétérol/effets indésirables , Glycopyrronium/effets indésirables , Indanes/effets indésirables
2.
Indian J Exp Biol
;
1992 Jul; 30(7): 583-6
Article
Dans Anglais
| IMSEAR
| ID: sea-56077
Résumé
In line of the effort towards development of some newer indanyl non-steroidal anti-inflammatory agents and providing comprehensive SAR among this class of compounds some significantly active derivatives with low ulcerogenic potential were identified. Dealing with various long chain and branched chain compounds among this series, 3-(5, 6-dimethoxy indan-1-yl) propionic acid, 2-(5, 6-dimethoxy indan-1-yl) propionic acid and 3-(6-methoxy indan-1-yl) propionic acid were observed to have encouraging biological activity. Screening in various animal models of inflammation suggests their longer duration of action and lower ulcerogenic liability.